The National Right to Life Committee has sent a formal letter to FDA Commissioner Dr. Marty Makary calling for a comprehensive review of the abortion drug mifepristone.
Citing a newly released study by the Ethics & Public Policy Center analyzing over 865,000 cases, NRLC raises grave concerns about the real-world complications and risks associated with chemical abortions—risks that have been downplayed or ignored by prior FDA assessments and abortion industry-backed research.
The letter calls for a reassessment of recent FDA decisions to deregulate mifepristone distribution, citing foreign studies and alarming data on emergency room visits, missed ectopic pregnancies, and unreported adverse events.
View, download, or print the full letter below: